These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 10753068

  • 1. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
    Schneider H, Adebakin S, Themis M, Cook T, Douar AM, Pavirani A, Coutelle C.
    J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068
    [Abstract] [Full Text] [Related]

  • 2. Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein.
    Themis M, Schneider H, Kiserud T, Cook T, Adebakin S, Jezzard S, Forbes S, Hanson M, Pavirani A, Rodeck C, Coutelle C.
    Gene Ther; 1999 Jul; 6(7):1239-48. PubMed ID: 10455432
    [Abstract] [Full Text] [Related]

  • 3. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA.
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease.
    Mühle C, Neuner A, Park J, Pacho F, Jiang Q, Waddington SN, Schneider H.
    Gene Ther; 2006 Dec; 13(23):1665-76. PubMed ID: 16871230
    [Abstract] [Full Text] [Related]

  • 5. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA.
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [Abstract] [Full Text] [Related]

  • 6. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
    Poller W, Schneider-Rasp S, Liebert U, Merklein F, Thalheimer P, Haack A, Schwaab R, Schmitt C, Brackmann HH.
    Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
    [Abstract] [Full Text] [Related]

  • 7. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA.
    Trans Am Clin Climatol Assoc; 2003 Jun; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [Abstract] [Full Text] [Related]

  • 8. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice.
    Smith TA, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, McClelland A, Kaleko M.
    Nat Genet; 1993 Dec; 5(4):397-402. PubMed ID: 8298650
    [Abstract] [Full Text] [Related]

  • 9. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, Herzog RW, High KA.
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [Abstract] [Full Text] [Related]

  • 10. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
    Schneider H, Mühle C, Douar AM, Waddington S, Jiang QJ, von der Mark K, Coutelle C, Rascher W.
    J Gene Med; 2002 Sep; 4(1):46-53. PubMed ID: 11828387
    [Abstract] [Full Text] [Related]

  • 11. Towards gene therapy for haemophilia B using primary human keratinocytes.
    Gerrard AJ, Hudson DL, Brownlee GG, Watt FM.
    Nat Genet; 1993 Feb; 3(2):180-3. PubMed ID: 8499952
    [Abstract] [Full Text] [Related]

  • 12. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
    Bilbao R, Reay DP, Wu E, Zheng H, Biermann V, Kochanek S, Clemens PR.
    Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
    [Abstract] [Full Text] [Related]

  • 13. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
    Peng JQ, Dong XY, Peng M, Chen L, Tan SP, Yuan H, Chen FP, Xue JL, Wu XB.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
    [Abstract] [Full Text] [Related]

  • 14. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors.
    Mitchell M, Jerebtsova M, Batshaw ML, Newman K, Ye X.
    Gene Ther; 2000 Dec; 7(23):1986-92. PubMed ID: 11175309
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. No evidence for germ-line transmission following prenatal and early postnatal AAV-mediated gene delivery.
    Jakob M, Mühle C, Park J, Weiss S, Waddington S, Schneider H.
    J Gene Med; 2005 May; 7(5):630-7. PubMed ID: 15693035
    [Abstract] [Full Text] [Related]

  • 18. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
    Wen J, Vargas AG, Ofosu FA, Hortelano G.
    J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997
    [Abstract] [Full Text] [Related]

  • 19. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice.
    Yao SN, Smith KJ, Kurachi K.
    Gene Ther; 1994 Mar; 1(2):99-107. PubMed ID: 7584074
    [Abstract] [Full Text] [Related]

  • 20. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.
    Kikuchi J, Mimuro J, Ogata K, Tabata T, Ueda Y, Ishiwata A, Kimura K, Takano K, Madoiwa S, Mizukami H, Hanazono Y, Kume A, Hasegawa M, Ozawa K, Sakata Y.
    J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.